dc.contributor.author | Karakaş, Nihal | |
dc.contributor.author | Üçüncüoğlu, Süleyman | |
dc.contributor.author | Uludağ, Damla | |
dc.contributor.author | Karaoğlan, Birnur Sinem | |
dc.contributor.author | Shah, Khalid | |
dc.contributor.author | Öztürk, Gürkan | |
dc.date.accessioned | 2022-03-10T06:47:51Z | |
dc.date.available | 2022-03-10T06:47:51Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.citation | Karakaş, N., Üçüncüoğlu, S., Uludağ, D., Karaoğlan, B. S., Shah, K. ve Öztürk, G. (2022). Mesenchymal stem cell-based COVID-19 therapy: Bioengineering perspectives. Cells, 11(3). https://doi.org/10.3390/cells11030465 | en_US |
dc.identifier.issn | 2073-4409 | |
dc.identifier.uri | https://doi.org/10.3390/cells11030465 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/9108 | |
dc.description.abstract | The novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Mesenchymal stem cells (MSCs) are currently utilized in clinics for pulmonary inflammatory diseases, including acute respiratory distress syndrome and acute lung injury. Given that MSCs offer a promising treatment against COVID-19, they are being used against COVID-19 in more than 70 clinical trials with promising findings. Genetically engineered MSCs offer promising therapeutic options in pulmonary diseases. However, their potential has not been explored yet. In this review, we provide perspectives on the functionally modified MSCs that can be developed and harnessed for COVID-19 therapy. Options to manage the SARS-CoV-2 infection and its variants using various bioengineering tools to increase the therapeutic efficacy of MSCs are highlighted. | en_US |
dc.description.sponsorship | Health Institute of Turkey (TUSEB) | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | ACE2 | en_US |
dc.subject | Bioengineering | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Genetic Engineering | en_US |
dc.subject | Mesenchymal Stem Cells | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | TMPRSS2 | en_US |
dc.title | Mesenchymal stem cell-based COVID-19 therapy: Bioengineering perspectives | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Cells | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyoloji Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER) | en_US |
dc.department | İstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü | en_US |
dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyofizik Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji ve Genetik Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Fizyoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-9096-1512 | en_US |
dc.authorid | 0000-0003-0352-1947 | en_US |
dc.identifier.volume | 11 | en_US |
dc.identifier.issue | 3 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.3390/cells11030465 | en_US |
dc.institutionauthor | Karakaş, Nihal | |
dc.institutionauthor | Üçüncüoğlu, Süleyman | |
dc.institutionauthor | Uludağ, Damla | |
dc.institutionauthor | Karaoğlan, Birnur Sinem | |
dc.institutionauthor | Öztürk, Gürkan | |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.wos | 000760495400001 | en_US |
dc.identifier.scopus | 2-s2.0-85123603605 | en_US |
dc.identifier.pmid | 35159275 | en_US |
dc.identifier.scopusquality | Q1 | en_US |